Tenderwize
Back to tender search

Open house discount agreements for active substance Tolvaptan, ATC G04BX21

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 29, 2028 · 557 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Tolvaptan, ATC G04BX21

30/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

30 / 100

Complexity

20 / 100

Risk factors

The buyer reserves the right to replace open house agreements with exclusive contracts during the term, which automatic...

No estimated value or volume is provided. Revenue potential is unclear, and the agreements may yield minimal discount-b...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Conclusion of non-exclusive discount agreements for pharmaceuticals with active substance Tolvaptan (ATC G04BX21)
  • Open house model: all eligible pharmaceutical companies can join on uniform terms
Show full summary

Open house non-exclusive discount agreements for the active substance Tolvaptan (ATC G04BX21) by AOK Rheinland-Pfalz/Saarland. All pharmaceutical companies can join on uniform terms from May 2026 to April 2028. No estimated value provided. The procedure is not a formal public procurement but published for transparency.

Risks

The buyer reserves the right to replace open house agreements with exclusive contracts during the term, which automatic...

No estimated value or volume is provided. Revenue potential is unclear, and the agreements may yield minimal discount-b...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Products must be authorized and marketable in Germany (listed in Lauer-Taxe or AMIce database)

Eligibility

  • Only pharmaceutical companies are eligible to participate

Administrative

  • Submission of signed contract documents either in paper (two copies, plus scan) or electronically with qualified electronic signature

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria; all eligible pharmaceutical companies are accepted under uniform conditions.

Buyer

Lots (1)

LOT-0001

Open house discount agreements for active substance Tolvaptan, ATC G04BX21

Non-exclusive rebate contracts for Tolvaptan products. Open to all pharmaceutical companies with authorized and marketable products in Germany. Uniform conditions, no negotiation. Maximum 24-month term, earliest start 01.05.2026. Buyer may replace with exclusive contracts during the term, terminating open house agreements automatically.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

Apr 2026 - Apr 2028

Category

Pharmaceutical products

Award Criteria

No award criteria; all eligible pharmaceutical companies are accepted under uniform conditions.

Deadline

Deadline Feb 29, 2028

Procurement Details

Publication date
15 Mar 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
178098-2026

Documents (1)

Similar tenders